PMPRB Report: Alignment Among Public Formularies in Canada, Part 2: Oncology Medicines

Visit to read the full report from Canada’s Patented Medicine Pricing Review Board (PMPRB).

The current report, Part 2 in the Alignment of Public Formularies in Canada series, addresses the public coverage of oncology medicines reviewed by the Canadian Agency for Drugs and Technologies in Health’s (CADTH) interim Joint Oncology Drug Review (iJODR) or pan-Canadian Oncology Drug Review (pCODR), as of the end of March 2020. In addition to a comparison of the formulary listings, the report unpacks specific oncology market segments, including hospital and take-home, biologic and small molecule, and single- and multi-source medicines.


0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply